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We read with interest the paper by Kalliokoski et al (Kalliokoski et al., 2020), investigating whether peripheral blood mononuclear cells (PBMCs) collected from patients with dermatitis herpetiformis (DH) undergoing a three-day oral gluten challenge react to gluten-derived gliadin in the enzyme linked immunospot (ELISpot) assay similarly to those of patients with celiac disease (CD). Interestingly, the Authors found that upon stimulation with tissue transglutaminase (tTG)-gliadin or either of the gliadin peptides, 7 of the 15 (47%) patients with DH and 15 of the 18 (83%) patients with CD were considered responders in the interferon (IFN)- ELISpot assay.
The Authors hypothesized that the percentage of responding patients with DH was significantly lower than that of patients with CD, possibly because of the significantly longer duration of gluten-free diet for patients with DH before the challenge. This is an intriguing hypothesis, suggesting that the immune tolerance can be restored  just avoiding the environmental trigger (gluten) for a reasonably long period of time. 
However, another explanation is possible for this different rate of responders. In fact, as it was previously demonstrated, in patients with DH the immune response is oriented towards a T helper 2 (Th2)-type pathway. Th2-related markers like interleukin (IL)-4 and IL-5 are overexpressed both in the skin (Caproni et al., 1998) and in the serum of patients with DH (Caproni et al., 2002; Makino et al., 2017). By contrast, it is well known that celiac disease is associated with a Th1 (and Th17)-oriented autoimmune response, with a primary role for IFN- (Castellanos-Rubio A et al., 2009). Therefore, it is not unexpected that a IFN-gamma ELISpot assay would have produced  higher percentages of positive CD patients than DH ones; by contrast, a IL-4 ELISpot assay would have been a more appropriate tool to investigate the reactivity of DH-derived PBMCs.
Moreover, epidermal TG (eTG) is now considered as the main autoantigen of DH and anti-eTG antibodies are found in both DH and CD (Antiga et al., 2019). Accordingly, to assess whether an ELISpot assay could predict clinical relapse in patients with DH, the use of eTG as the autoantigen and the detection of IL-4 expression as the sign of PBMCs activation should be added to increase sensitivity and reliability to the IFN-gamma ELISPOT assay performed with tTG and gluten-derived peptides.
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